12:00 AM
 | 
Jun 23, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

HA-Irinotecan: Phase III ongoing

Alchemia said it now expects to report top-line data from the double-blind, international Phase III ACO002 trial of HA-Irinotecan before the end of 3Q14. The company, which previously said it expected data this half, said the update is due to longer duration of PFS, which...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >